Dawn Scholdant
Senior Vice President, Investor Relations and Corporate Affairs
Replay available
Geron Corporation (GERN) Q3 2025 Earnings Call
Geron Corporation (NASDAQ: GERN) Q3 2025 earnings conference call, held 2025-11-05. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Harut Samarjian
Chief Executive Officer
Joseph Ede
Executive Vice President of Research and Development and Chief Medical Officer
Michelle Robertson
Chief Financial Officer
Ahmed El-Nawawi
Chief Commercial Officer
Tara Bancroft
Analyst, TD Cowen
Steven Wiley
Analyst, Stifel
Emily Bodnar
Analyst, H.C. Wainwright
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Geron Corporation.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.299 like to ask a question during this time, please press star 1 on your telephone keypad. 00:00:05.299 -- 00:00:09.105 I would now like to turn the call over to Dawn Scholdant, 00:00:09.105 -- 00:00:13.151 Senior Vice President, Investor Relations and Corporate Affairs. 00:00:13.151 -- 00:00:15.134 You may begin. 00:00:15.134 -- 00:00:20.803 Good morning, everyone. Welcome to the Geron Corporation third quarter 2025 earnings 00:00:20.803 -- 00:00:22.646 conference call. 00:00:22.646 -- 00:00:26.532 Before we begin, please note that during the course of this presentation and question 00:00:26.532 -- 00:00:31.023 and answer session, We will be making forward-looking statements regarding future events, 00:00:31.023 -- 00:00:35.471 performance, plans, expectations, and other projections, including those relating to 00:00:35.471 -- 00:00:40.239 the launch, commercial opportunity, and therapeutic potential of Ritello, anticipated 00:00:40.239 -- 00:00:43.444 clinical and commercial events, and related timelines. 00:00:43.444 -- 00:00:47.350 The sufficiency of general financial resources and other statements that are not historical 00:00:47.350 -- 00:00:51.533 facts. Actual events or results could differ materially. 00:00:51.533 -- 00:00:55.919 Therefore, I refer you to the discussion under the heading Risk Factors in Jaron's most 00:00:55.919 -- 00:01:01.025 recent periodic report filed with the SEC, which identifies important factors that could 00:01:01.025 -- 00:01:05.110 cause actual results to differ materially from those contained in the forward-looking 00:01:05.110 -- 00:01:09.055 statements and our future updates to those risk factors. 00:01:09.055 -- 00:01:14.523 Jaron undertakes no duty or obligation to update our forward-looking s...